1,041 material Form 8-K filings that 824 companies we cover made with the SEC in November 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Marker Therapeutics reported third quarter 2025 results on November 14, 2025. The net loss narrowed to $2.0 million from $2.3 million a year earlier, but grant income fell to $1.2 million from $1.9 million, and the nine-month net loss widened to $10.5 million from $6.9 million. The company said its cash will fund operations through the third quarter of 2026, assuming no additional grant funds, after raising approximately $10 million through its ATM facility.
Q3 2025 grant income was $1.2 million, down from $1.9 million in Q3 2024
Q3 2025 net loss was $2.0 million ($0.12 per share), versus $2.3 million ($0.26 per share) a year earlier
Cash and cash equivalents were $17.6 million at September 30, 2025, plus $1.4 million restricted cash
Nine-month net loss was $10.5 million versus $6.9 million, including a $453,135 loss on early termination of a vendor agreement
Spire reported fiscal 2025 net income of $271.7 million ($4.37 per diluted share), up from $250.9 million a year earlier, and adjusted EPS of $4.44, up 7.5% from $4.13. Operating revenues fell to $2.48 billion from $2.59 billion, and the company issued adjusted EPS guidance of $5.25 to $5.45 for fiscal 2026 and $5.65 to $5.85 for fiscal 2027. The board also raised the quarterly common dividend 5.1% to $0.825 per share.
Fiscal 2025 adjusted earnings were $275.5 million ($4.44 per share) versus $247.4 million ($4.13 per share) in fiscal 2024
Operating revenues were $2,476.4 million versus $2,593.0 million; fourth-quarter net loss was $39.8 million ($0.74 per share) versus $25.9 million ($0.51 per share)
Fiscal 2026 adjusted EPS guidance of $5.25 to $5.45 excludes the pending Piedmont Natural Gas Tennessee acquisition; fiscal 2027 guidance of $5.65 to $5.85 includes it
Quarterly common dividend raised to $0.825 per share, payable January 5, 2026, to holders of record December 11, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.